@article{TGH4070,
author = {Irvin C. Lien and Seth M. Pollack},
title = {Limited activity of metronomic cyclophosphamide and pembrolizumab for soft tissue sarcomas},
journal = {Translational Gastroenterology and Hepatology},
volume = {3},
number = {1},
year = {2018},
keywords = {},
abstract = {Outcomes for patients with sarcoma remain poor with overall survival for patients in the metastatic setting typically in the range of 12 to 18 months (1). Programmed death 1 protein (PD-1) has become one of the most important targets in cancer immunotherapy (2), particularly for the many inflammatory cancers that contain PD-1 expressing T cells or cells expressing its ligand (PD-L1) (3). While recent studies have shown that some sarcoma patients may respond to PD-1 blockade, responses are highly subtype specific. Even in highly inflammatory subtypes such as undifferentiated pleomorphic sarcoma (UPS), responses are only seen in a minority of patients demonstrating the need for combination therapies that further improve patient outcome (4).},
issn = {2415-1289}, url = {https://tgh.amegroups.org/article/view/4070}
}